迈兰从Strides Arcolab收购Agila专业产品，促进全球注射剂业务

Pharmadeals Review Pub Date : 2013-12-03 DOI:10.3833/pdr.v2013i3.1909

Heather Cartwright

{"title":"迈兰从Strides Arcolab收购Agila专业产品，促进全球注射剂业务","authors":"Heather Cartwright","doi":"10.3833/pdr.v2013i3.1909","DOIUrl":null,"url":null,"abstract":"Putting an end to speculation about the future of the division, India’s Strides Arcolab has agreed to divest its generic injectables unit Agila Specialities to Mylan for US$1.6 B in cash plus up to an additional US$250 M subject to the satisfaction of certain conditions by Strides. The deal, which values Agila at 6.3 times 2012 sales and 18.6 times EBITDA, will provide Mylan with critical mass in injectable drugs and an entry into high-growth emerging markets such as Brazil.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"16 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Mylan Bolsters Global Injectables Business with Deal to Acquire Agila Specialities from Strides Arcolab\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2013i3.1909\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Putting an end to speculation about the future of the division, India’s Strides Arcolab has agreed to divest its generic injectables unit Agila Specialities to Mylan for US$1.6 B in cash plus up to an additional US$250 M subject to the satisfaction of certain conditions by Strides. The deal, which values Agila at 6.3 times 2012 sales and 18.6 times EBITDA, will provide Mylan with critical mass in injectable drugs and an entry into high-growth emerging markets such as Brazil.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"16 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-12-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2013i3.1909\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2013i3.1909","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

为了结束对该部门未来的猜测，印度的Strides Arcolab已同意以16亿美元的现金加上高达2.5亿美元的额外资金，将其非专利注射剂部门Agila Specialities出售给Mylan，前提是Strides满足某些条件。这笔交易对Agila的估值为2012年销售额的6.3倍，EBITDA的18.6倍。这笔交易将使Mylan在注射药物领域达到临界规模，并进入巴西等高增长新兴市场。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Mylan Bolsters Global Injectables Business with Deal to Acquire Agila Specialities from Strides Arcolab

Putting an end to speculation about the future of the division, India’s Strides Arcolab has agreed to divest its generic injectables unit Agila Specialities to Mylan for US$1.6 B in cash plus up to an additional US$250 M subject to the satisfaction of certain conditions by Strides. The deal, which values Agila at 6.3 times 2012 sales and 18.6 times EBITDA, will provide Mylan with critical mass in injectable drugs and an entry into high-growth emerging markets such as Brazil.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量